BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N, Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D, Paneth NS, Carter RE, Casadevall A, Joyner MJ. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne) 2021;8:684151. [PMID: 34164419 DOI: 10.3389/fmed.2021.684151] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Salma N, Hossain MM, Yasmin S, Alam MK, Rimon AR, Faruque J, Ali M. Factors influencing plasma donation behavior of COVID‐19 recovered patients in Bangladesh: A pilot study. Health Science Reports 2023;6. [DOI: 10.1002/hsr2.974] [Reference Citation Analysis]
2 Corrêa-junior D, Andrade IBD, Alves V, Araújo GRDS, Frases S. Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic. Microorganisms 2022;10:2223. [DOI: 10.3390/microorganisms10112223] [Reference Citation Analysis]
3 Gül F, Gonen ZB, Jones OY, Taşlı NP, Zararsız G, Ünal E, Özdarendeli A, Şahin F, Eken A, Yılmaz S, Karakukçu M, Kırbaş OK, Gökdemir NS, Bozkurt BT, Özkul Y, Oktay BD, Uygut MA, Cinel I, Çetin M. A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™). Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.963309] [Reference Citation Analysis]
4 Ferrari A, Cassaniti I, Sarasini A, Lilleri D, Sammartino JC, Del Fante C, Baldanti F, Percivalle E, Perotti C. Characterization of CCP: Can We Use Past Convalescent Plasma from COVID-19 Patients for Treatment of New Emerging Variants? COVID 2022;2:1564-1574. [DOI: 10.3390/covid2110112] [Reference Citation Analysis]
5 Laner-plamberger S, Lindlbauer N, Weidner L, Gänsdorfer S, Weseslindtner L, Held N, Lauth W, Zimmermann G, Kern JM, Föttinger F, Ombres L, Jungbauer C, Rohde E, Grabmer C. SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability. Diagnostics 2022;12:2567. [DOI: 10.3390/diagnostics12112567] [Reference Citation Analysis]
6 Joyner MJ, Carter RE, Fairweather D, Wright RS. Convalescent plasma and COVID ‐19: Time for a second—second look? Transfusion Medicine. [DOI: 10.1111/tme.12915] [Reference Citation Analysis]
7 Aldunate F, Fajardo A, Rammauro F, Daghero H, Arce R, Ferla D, Pereira-gomez M, Ibañez N, Salazar C, Iraola G, Pritsch O, Bollati M, Hurtado J, Tenzi J, Bianchi S, Nin N, Moratorio G, Moreno P. ¿What did we learn from Convalescent plasma treatment in a COVID-19 patient two-time kidney transplanted? A case report from the viral and immune response evolution perspective.. [DOI: 10.21203/rs.3.rs-1930278/v1] [Reference Citation Analysis]
8 Puopolo M, Morciano C, Buoncervello M, De Nuccio C, Potenza RL, Toschi E, Palmisano L. Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic. Trials 2022;23:527. [PMID: 35733167 DOI: 10.1186/s13063-022-06474-8] [Reference Citation Analysis]
9 Kurtović T, Ravlić S, Štimac A, Mateljak Lukačević S, Hećimović A, Kazazić S, Halassy B. Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks. Front Immunol 2022;13:889736. [PMID: 35655779 DOI: 10.3389/fimmu.2022.889736] [Reference Citation Analysis]
10 Chavda VP, Bezbaruah R, Athalye M, Parikh PK, Chhipa AS, Patel S, Apostolopoulos V. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses 2022;14:759. [DOI: 10.3390/v14040759] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
11 Mahalingam G, Rachamalla HK, Arjunan P, Periyasami Y, M S, Thangavel S, Mohankumar KM, Moorthy M, Velayudhan SR, Srivastava A, Marepally S. Optimization of SARS-CoV-2 Pseudovirion Production in Lentivirus Backbone With a Novel Liposomal System. Front Pharmacol 2022;13:840727. [DOI: 10.3389/fphar.2022.840727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Clark NM, Janaka SK, Hartman W, Stramer S, Goodhue E, Weiss J, Evans DT, Connor JP. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. PLoS One 2022;17:e0257930. [PMID: 35259162 DOI: 10.1371/journal.pone.0257930] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
13 Ravlić S, Hećimović A, Kurtović T, Ivančić Jelečki J, Forčić D, Slović A, Kurolt IC, Mačak Šafranko Ž, Mušlin T, Rnjak D, Jakšić O, Sorić E, Džepina G, Đaković Rode O, Kujavec Šljivac K, Vuk T, Jukić I, Markotić A, Halassy B. Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible? Front Immunol 2022;13:816159. [PMID: 35273599 DOI: 10.3389/fimmu.2022.816159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Güven BB, Ertürk T, Yildiz E, Durmayüksel E, Ersoy A, Tanoğlu A. Our convalescent plasma experiences in COVID-19 patients hospitalized in the intensive care unit. Journal of Health Sciences and Medicine 2022;5:600-6. [DOI: 10.32322/jhsm.1068864] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022;:e0020021. [PMID: 35262370 DOI: 10.1128/cmr.00200-21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
16 Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiridou-chatzopoulou M, Papazoglou DD, Doulberis M. Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Medicina 2022;58:309. [DOI: 10.3390/medicina58020309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 De Silvestro G, Marson P, La Raja M, Cattelan AM, Guarnieri G, Monticelli J, Tiberio I, Vianello A, Gandini G, Gessoni G, Fiorin F, Sardella C, Astolfi L, Saia M; Veneto Hospitals. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. Eur J Intern Med 2021:S0953-6205(21)00433-7. [PMID: 34980505 DOI: 10.1016/j.ejim.2021.12.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
18 Khamis F, Al Awaidy S, Shaaibi MA, Shukeili MA, Chhetri S, Balushi AA, Sulaimi SA, Balushi AA, Wesonga R. Epidemiological Characteristics of Hospitalized Patients with Moderate versus Severe COVID-19 Infection: A Retrospective Cohort Single Centre Study. Diseases 2021;10:1. [PMID: 35076497 DOI: 10.3390/diseases10010001] [Reference Citation Analysis]
19 Melani RD, Des Soye BJ, Kafader JO, Forte E, Hollas M, Blagojevic V, Negrão F, McGee JP, Drown B, Lloyd-Jones C, Seckler HS, Camarillo JM, Compton PD, LeDuc RD, Early B, Fellers RT, Cho BK, Mattamana BB, Goo YA, Thomas PM, Ash MK, Bhimalli PP, Al-Harthi L, Sha BE, Schneider JR, Kelleher NL. Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. J Proteome Res 2021. [PMID: 34878788 DOI: 10.1021/acs.jproteome.1c00882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Husniah H, Ruhanda R, Supriatna AK, Biswas MHA. SEIR Mathematical Model of Convalescent Plasma Transfusion to Reduce COVID-19 Disease Transmission. Mathematics 2021;9:2857. [DOI: 10.3390/math9222857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Arnold Egloff SA, Junglen A, Restivo JS, Wongskhaluang M, Martin C, Doshi P, Schlauch D, Fromell G, Sears LE, Correll M, Burris HA 3rd, LeMaistre CF. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J Clin Invest 2021;131:e151788. [PMID: 34464352 DOI: 10.1172/JCI151788] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 24.0] [Reference Citation Analysis]
22 Alape-Girón A, Moreira-Soto A, Arguedas M, Brenes H, Buján W, Corrales-Aguilar E, Díaz C, Echeverri A, Flores-Díaz M, Gómez A, Hernández A, Herrera M, León G, Macaya R, Molina-Mora JA, Mora J, Narayanan A, Sanabria A, Sánchez A, Sánchez L, Segura Á, Segura E, Solano D, Soto C, Stynoski JL, Vargas M, Villalta M, Drexler JF, Gutiérrez JM. Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19. Front Med (Lausanne) 2021;8:743325. [PMID: 34552950 DOI: 10.3389/fmed.2021.743325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Focosi D, Franchini M, Pirofski L, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy.. [DOI: 10.1101/2021.09.07.21263194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Clark NM, Janaka SK, Hartman W, Stramer S, Goodhue E, Weiss J, Evans DT, Connor JP. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection. bioRxiv 2021:2021. [PMID: 34545365 DOI: 10.1101/2021.09.14.460394] [Reference Citation Analysis]
25 Garraud O, Burnouf T. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps. Transfus Clin Biol 2021;28:225-7. [PMID: 34362557 DOI: 10.1016/j.tracli.2021.07.005] [Reference Citation Analysis]
26 Natarajan H, Xu S, Crowley AR, Butler SE, Weiner JA, Bloch EM, Littlefield K, Benner SE, Shrestha R, Ajayi O, Wieland-alter W, Sullivan D, Shoham S, Quinn TC, Casadevall A, Pekosz A, Redd AD, Tobian AA, Connor RI, Wright PF, Ackerman ME. Antibody Attributes that Predict the Neutralization and Effector Function of Polyclonal Responses to SARS-CoV-2.. [DOI: 10.1101/2021.08.06.21261710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Joyner MJ, Klompas AM, Klassen SA, Senefeld JW, Fairweather D, Wright RS, Carter RE. In Reply-How Safe Is COVID-19 Convalescent Plasma? Mayo Clin Proc 2021;96:2281-2. [PMID: 34353476 DOI: 10.1016/j.mayocp.2021.06.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]